Switching to Less Expensive Insulin May Be Possible, Study Shows

The US drug market has seen a significant increase in the price of insulin over the past 2 decades. Although the price has increased for all forms of insulin, newer, “analogue” insulin medications, such as glargine and lispro, can cost 2 to 10 times more than less expensive human insulin, such as human neutral protamine Hagedorn (NPH). In fact, Medicare’s outpatient prescription drug program (Part D) spent more than $4 billion on just 1 long-acting analogue insulin in 2016.

View Article